Optimized Cell-Based Delivery & Potentiation of Oncolytic Virotherapies
Time: 9:30 am
day: Day Two
Details:
- The novel Calidi’s platform leverages allogeneic stem cells, combined with an oncolytic virus payload, which prevents the viral elimination by the patient’s immune system, and facilitates initial viral amplification and expansion at the tumor sites
- Calidi’s final product contains not only stem cells loaded with viral particles, but also immune modulatory cytokines produced by the stem cells as well as virally encoded proteins (natural or engineered). Therefore, the tumor microenvironment (TME) is modified immediately upon intratumoral injection to support effective viral amplification, oncolysis and immune modulation
- Pre-clinical and initial clinical data in multiple tumor types have demonstrated potent anti-tumor effects of Calidi’s approach not only at the injected tumor site, but also at distant metastatic tumor sites. Importantly, there are significant, clinically documented synergistic effects of this approach with checkpoint inhibition
